Yesterday, the U.S. Food and Drug Administration approved the use of Trikafta® (elexacaftor/tezacaftor/ivacaftor) for children with cystic fibrosis ages 2-5 years who have at least one copy of the F508del mutation, or one copy of certain mutations. With this approval, approximately 2,250 children are now eligible for this transformative treatment, including more than 900 who will have access to a CFTR modulator for the first time.

Read the announcement »

Today, Congress reintroduced the PASTEUR Act, which will revitalize the antibiotic development pipeline. For people with cystic fibrosis, more, novel antibiotics means more options to fight off deadly infections that put so much progress in jeopardy. Now it's our turn: tell Congress to pass this bill without delay.

Act now »

May is CF Awareness Month, a celebration to come together and honor the CF community. We encourage you to get involved by sharing your unique story and experiences on social media, or by downloading custom graphics to help raise CF awareness.

Download CF Awareness Month graphics »

Last week, we celebrated National Volunteer Week, recognizing our incredible volunteers for their dedication and commitment to the CF community. During Gratitude Hour, Adam Brostowitz, an adult with CF; Eileen McConville, a parent of an adult with CF; Maria Znidarsic, an adult with CF; and Andrea Rodriguez, an adult with CF; shared what motivates their relentless fight against CF.

Watch on YouTube »